506414 Stock Overview
Manufactures and markets chemicals, bulk drugs, enzymes in India, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
Fermenta Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹379.95 |
| 52 Week High | ₹440.00 |
| 52 Week Low | ₹145.00 |
| Beta | 0.15 |
| 1 Month Change | 2.48% |
| 3 Month Change | 27.01% |
| 1 Year Change | 135.92% |
| 3 Year Change | 34.12% |
| 5 Year Change | 49.88% |
| Change since IPO | 3,699.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 506414 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.9% | 1.3% | -3.2% |
| 1Y | 135.9% | 39.0% | 18.7% |
Return vs Industry: 506414 exceeded the Indian Pharmaceuticals industry which returned 39% over the past year.
Return vs Market: 506414 exceeded the Indian Market which returned 18.7% over the past year.
Price Volatility
| 506414 volatility | |
|---|---|
| 506414 Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 506414's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 506414's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1951 | 558 | Prashant Nagre | fermentabiotech.com |
Fermenta Biotech Limited, together with its subsidiaries, manufactures and markets chemicals, bulk drugs, enzymes in India, Europe, the United States, and internationally. The company engages in the pharmaceutical formulations and environmental solutions; rents and sales properties; and sports and health awareness/education activities. It offers various variants of vitamin D3, including crystalline oil, resin oil, cold water dispersible, and feed grade powder used in applications, such as pharmaceuticals, dietary and nutritional supplements, feed, injectables, soft gel capsules, premixes, food and beverage fortification, veterinary, feed and rodenticides; pharmaceutical ingredients comprising of phenyramidol and silicon dry powder; nutritional premixes; and enzymes, used in pharmaceuticals, food and fragrances, oleo, biodiesel, leather, fine chemical, bio-plastics, and cosmetic industries.
Fermenta Biotech Limited Fundamentals Summary
| 506414 fundamental statistics | |
|---|---|
| Market cap | ₹11.18b |
| Earnings (TTM) | ₹84.68m |
| Revenue (TTM) | ₹3.69b |
132.0x
P/E Ratio3.0x
P/S RatioIs 506414 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 506414 income statement (TTM) | |
|---|---|
| Revenue | ₹3.69b |
| Cost of Revenue | ₹1.48b |
| Gross Profit | ₹2.22b |
| Other Expenses | ₹2.13b |
| Earnings | ₹84.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.88 |
| Gross Margin | 60.02% |
| Net Profit Margin | 2.29% |
| Debt/Equity Ratio | 41.5% |
How did 506414 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield-16%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 00:45 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fermenta Biotech Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nikhil Shetty | BP Wealth Management Private Limited |